C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
260/277.35
C07D 471/20 (2006.01) C07D 498/10 (2006.01) C07D 513/10 (2006.01)
Patent
CA 1292992
4680-338 Abstract Spiro-heteroazolones of the formula below are disclosed which are useful as aldose reductase inhibitors and as therapeutic agents for the treat- ment of complications arising from diabetes: Image I or a pharmaceutically acceptable salt thereof, wherein A is methylene, hydroxy- methylene, or methine; Y is methylene, alkylmethylene, methine or alkyl- methine, wherein alkyl in each instance has 1-4 carbon atoms; with the proviso that when A is methine, Y is methine or alkylmethine; Z is oxygen, sulfur, or nitrogen substituted by hydrogen; Q is nitrogen or nitrogen-N-oxide; and X is in the 3'-position and is hydrogen, halo, alkyl, alkoxy having 1-4 carbon atoms, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, phenylthio, or nitro; or X is in the 2'-position and is hydrogen, alkyl, or alkoxy having 1-4 carbon atoms; wherein alkyl in each instance has 1-4 carbon atoms; with the proviso that when Q is nitrogen-N-oxide, X is not alkylthio, alkylsulfinyl or phenylthio; and with the further proviso that when Q is nitrogen and X is hydrogen and Z is nitrogen substituted by hydrogen, at least one of A and Y is always other than methylene.
493949
Pfizer Inc.
Smart & Biggar
LandOfFree
Spiro-heteroazolones for treatment of diabetes complications does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Spiro-heteroazolones for treatment of diabetes complications, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spiro-heteroazolones for treatment of diabetes complications will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1238143